News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
23,520 Results
Type
Article (2993)
Company Profile (4)
Press Release (20523)
Section
Business (7910)
Career Advice (75)
Deals (1034)
Drug Delivery (8)
Drug Development (4005)
Employer Resources (7)
FDA (675)
Job Trends (687)
News (13136)
Policy (1049)
Tag
Academia (72)
Alliances (2063)
Alzheimer's disease (82)
Antibody-drug conjugate (ADC) (10)
Approvals (669)
Artificial intelligence (10)
Bankruptcy (4)
Best Places to Work (496)
Biosimilars (8)
Breast cancer (13)
Cancer (85)
Career advice (65)
Cell therapy (11)
Clinical research (3109)
Collaboration (19)
COVID-19 (208)
C-suite (8)
Data (35)
Diabetes (11)
Diagnostics (222)
Earnings (1987)
Employer resources (6)
Events (2080)
Executive appointments (20)
FDA (688)
Funding (11)
Gene therapy (12)
GLP-1 (51)
Government (176)
Healthcare (508)
Immunology and inflammation (5)
Infectious disease (210)
Inflammatory bowel disease (12)
Influenza (4)
Interviews (7)
IPO (329)
Job creations (215)
Job search strategy (60)
Layoffs (44)
Legal (209)
Liver cancer (12)
Lung cancer (15)
Lymphoma (7)
Manufacturing (15)
Medical device (166)
Medtech (166)
Mergers & acquisitions (710)
Metabolic disorders (33)
Multiple sclerosis (11)
Neurodegenerative disease (5)
Neuroscience (101)
NextGen Class of 2024 (197)
Non-profit (151)
Northern California (56)
Obesity (21)
Opinion (21)
People (3390)
Phase I (974)
Phase II (1290)
Phase III (1278)
Pipeline (18)
Podcasts (7)
Policy (4)
Postmarket research (194)
Preclinical (299)
Radiopharmaceuticals (9)
Rare diseases (7)
Real estate (182)
Regulatory (751)
Reports (6)
Research institute (92)
Resumes & cover letters (11)
Southern California (39)
Startups (174)
The Weekly (7)
United States (379)
Vaccines (29)
Weight loss (20)
Date
Today (7)
Last 7 days (31)
Last 30 days (124)
Last 365 days (1223)
2024 (1098)
2023 (1242)
2022 (2615)
2021 (2279)
2020 (2018)
2019 (1367)
2018 (1149)
2017 (1058)
2016 (995)
2015 (1313)
2014 (912)
2013 (756)
2012 (908)
2011 (1026)
2010 (1003)
Location
Africa (55)
Arizona (8)
Asia (1146)
Australia (174)
California (112)
Canada (14)
China (9)
Europe (4351)
Illinois (12)
Maryland (5)
Massachusetts (55)
Minnesota (5)
New Jersey (18)
New York (60)
North Carolina (11)
Northern California (56)
Pennsylvania (6)
South America (50)
Southern California (39)
Texas (6)
Utah (6)
Washington State (72)
23,520 Results for "roche".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Weight loss
Roche’s Obesity Pill Candidate Hit With Safety Concerns Despite Strong Efficacy Data
When doses were increased rapidly in a Phase I study, patients on Roche’s investigational oral GLP-1 receptor agonist experienced nausea, vomiting, constipation, diarrhea, as well as abdominal distension.
September 12, 2024
·
2 min read
·
Tristan Manalac
Earnings
Roche Beats Q3 Sales Estimates as CEO Voices Opposition to Novo Holdings’ Catalent Buyout
Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by strong performance of its multiple sclerosis therapy Ocrevus and eye injection Vabysmo.
October 23, 2024
·
3 min read
·
Tristan Manalac
Deals
Roche Inks Potential $1.8B Deal With Flare to Target Transcription Factors in Cancer
With $70 million upfront and more than $1.8 billion on the line, Roche will gain access to Flare’s drug discovery engine to bolster its oncology pipeline.
November 12, 2024
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Roche Looks to Push Gazyva Into Lupus Nephritis With Promising Late-Stage Data
In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis versus placebo, positioning Roche’s therapeutic antibody for expansion into the indication.
September 27, 2024
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Roche Trims Another Alzheimer’s Prospect, Ending UCB Collabortion
Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to work together on new treatments for the neurological disease.
October 22, 2024
·
1 min read
·
Annalee Armstrong
M&A
Roche Doubles Down on Breast Cancer With $850M for Regor’s CDK Inhibitors
The acquisition was featured Monday in Roche’s Pharma Day presentation, which also included projections of more than $3 billion in annual sales from three early-stage obesity and diabetes drugs.
September 30, 2024
·
2 min read
·
Heather McKenzie
Approvals
Roche Gains PD-1 Edge on Merck With FDA Nod for Subcutaneous Tecentriq
Tecentriq Hybreza, which combines Roche’s Tecentriq with Halozyme Therapeutics’ Enhanze drug delivery technology, is being touted as the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy.
September 13, 2024
·
2 min read
·
Tristan Manalac
Gene therapy
Roche Inks Potential $1B Gene Therapy Deal With Dyno, Eyes Neurological Diseases
With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’
in vivo
gene therapy delivery technology, which synthesizes virus capsids with better functionality and manufacturability.
October 24, 2024
·
2 min read
·
Tristan Manalac
Approvals
Roche Wins First-Line Breast Cancer Nod for Oral PI3K Blocker, Projects $2.3B in Peak Sales
With the regulatory approval for advanced breast cancer, Roche’s inavolisib is a potential challenger to Novartis’ PI3K inhibitor Piqray, which last year generated $505 million in revenue.
October 11, 2024
·
2 min read
·
Tristan Manalac
Podcast
BMS’ Schizophrenia Approval, Pfizer’s Sudden Sickle Cell Withdrawal and Roche’s Pharma Day
Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; new IVF and abortion laws could derail women’s health research; Roche touts CDK inhibitor deal and obesity pipeline and
BioSpace
heads to Meeting on the Mesa.
October 2, 2024
·
1 min read
·
Heather McKenzie
1 of 2,352
Next
